immunotherapy

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences, Inc. (NASDAQ: GILD) announced Thursday that it has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These inve..

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Therapeutics Inc. (NASDAQ: JUNO) shares continued to surge on Monday after Celgene Corp. (NASDAQ: CELG) had entered into an agreement to acquire Juno for a total of $9 billion or $87 per share. Juno shares rose 27 percent during Monday&rsq..